• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Andrology >Testosterone replacement therapy for male aging: ASA position statement.
【24h】

Testosterone replacement therapy for male aging: ASA position statement.

机译：男性衰老的睾丸激素替代疗法：ASA立场声明。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The American Society of Andrology suggests that testosterone replacement therapy in aging men is indicated when both clinical symptoms and signs suggestive of androgendeficiency and decreased testosterone levels are present. Testosterone replacement may also be warranted in older men with markedly decreased testosterone levels regardless of symptoms, but signs of androgen deficiency should be present. Based on the data currently available, the measurement of total blood testosterone is the most appropriate and widely available test to confirm hypogonadism.Subject to future research, a total testosterone level of 300 ng/dL measured in the morning, using a reliable assay, may be used as a threshold below which an individual can be considered hypogonadal. The American Society of Andrology recommends periodic monitoring of men receiving testosterone replacement therapy. Subject to individual clinical response, evaluation is recommended at 3 to 6 months after initiation of therapy, and then yearly. A physical examination, including digital rectal examination of the prostate, a prostate-related symptom assessment, prostate-specific antigen (PSA) level, and hematocrit,should be performed at 3, 6, and 12 months, and then annually. Testosterone therapy should be altered or ended if the hematocrit exceeds 52%, Contraindications to therapy include a history of prostate cancer, breast cancer, untreated sleep apnea, and untreated and/or severe congestive heart failure.
机译：美国男科学会建议，当存在雄激素缺乏症和睾丸激素水平降低的临床症状和体征同时出现时，则建议在老年男性中使用睾丸激素替代疗法。睾丸激素水平明显降低的老年男性也可能需要更换睾丸激素，而不论症状如何，但应出现雄激素缺乏的迹象。根据目前可用的数据，全血睾丸激素的测定是确定性腺功能减退的最合适且广泛可用的检查方法，但有待进一步研究，早晨使用可靠的测定方法测得的总睾丸激素水平为300 ng / dL。用作阈值，低于此阈值可将个人视为性腺功能减退。美国男科学会建议定期监测接受睾丸激素替代疗法的男性。根据个人的临床反应，建议在开始治疗后的3至6个月进行评估，然后每年进行评估。应当在3、6和12个月（每年）进行一次身体检查，包括前列腺数字直肠检查，前列腺相关症状评估，前列腺特异性抗原（PSA）水平和血细胞比容。如果血细胞比容超过52％，则应更改或终止睾丸激素治疗。治疗的禁忌症包括前列腺癌，乳腺癌，未经治疗的睡眠呼吸暂停以及未经治疗和/或严重的充血性心力衰竭的病史。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号